Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03940586 · ClinicalTrials.gov registry record · Phase 2
Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)
A Phase 2 study of Cytomegalovirus (CMV) Infection, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
- 20
- Study locations
NCT03940586 is a Phase 2 study of Cytomegalovirus (CMV) Infection that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 65 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT03940586, a Phase 2 study of Cytomegalovirus (CMV) Infection, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of letermovir (LET) in pediatric participants. Participants will be enrolled in the following 3 age groups: Age Group 1: From 12 to \<18 years of age (adolescents); Age Group 2: From 2 to \<12 years of age (children); and Age Group 3: From birth to \<2 years of age (neonates, infants and toddlers). All participants will receive open label LET for 14 weeks (\~100 days) post-transplant, with doses based on body weight and age.
Conditions Studied
Interventions
- DRUG Letermovir oral granules
- DRUG Letermovir tablet
- DRUG Letermovir intravenous
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center ( Site 0251) - Duarte
- Children's Hospital of Orange County ( Site 0241) - Orange
- UCSF Benioff Children's Hospital San Francisco ( Site 0245) - San Francisco
Valle del Cauca Department
- Fundacion Valle del Lili ( Site 0212) - Cali
- Centro Medico Imbanaco de Cali S.A ( Site 0211) - Cali
Illinois
- University Of Chicago School Of Medicine ( Site 0253) - Chicago
Massachusetts
- Boston Children's Hospital ( Site 0243) - Boston
New York
- Memorial Sloan Kettering Cancer Center ( Site 0254) - New York
North Carolina
- Duke University Health System ( Site 0252) - Durham
Ohio
- Cincinnati Children's Hospital Medical Center ( Site 0244) - Cincinnati
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC ( Site 0258) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2019-08-08 |
| Est. Completion | 2023-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03940586
The ClinicalTrials.gov registry entry for NCT03940586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cytomegalovirus (CMV) Infection appearing as the primary indexed condition, and to 3 interventions - of which Letermovir oral granules is the first listed.
NCT03940586 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Valle del Cauca Department, Illinois.
Frequently Asked Questions
What is clinical trial NCT03940586 about?
NCT03940586 is a clinical study titled "Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)". The primary objective of this study is to evaluate the pharmacokinetics (PK) of letermovir (LET) in pediatric participants. Participants will be enrolled in the following 3 age groups: Age Group 1: From 12 to \<18 years of age (adolescents); Age Group 2: From 2 to \<12 years of age (children); and A...
What is the current status of trial NCT03940586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2019-08-08. Estimated completion is 2023-08-25.
What conditions does trial NCT03940586 study?
This clinical trial studies the following conditions: Cytomegalovirus (CMV) Infection.
What interventions are being tested in trial NCT03940586?
The interventions under investigation include: Letermovir oral granules (DRUG), Letermovir tablet (DRUG), Letermovir intravenous (DRUG).
Who is sponsoring clinical trial NCT03940586?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03940586 being conducted?
This trial has 20 study locations across California, Illinois, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.